-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $875

Benzinga·05/19/2026 13:39:08
Listen to the news
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $1057 to $875.